Our results show that the inhibition of ALDH enzymes including ALDH3A1 by dyclonine cooperatively enhances the efficacy of xCT-targeted therapy by promoting accumulation of the toxic aldehyde 4-HNE in GSH deficiency-resistant cancer cells. Here, ALDH3A1 is linked to cancer.